Oracea phase 3 clinical trials show 'highly significant' results

July 1, 2005

Newtown, Pa. — CollaGenex Pharmaceuticals announces the "highly significant" positive outcomes of two phase 3, double-blinded, placebo-controlled clinical trials designed to evaluate the safety and efficacy of Oracea for the treatment of rosacea.